Journal: PLoS ONE

Article Title: Gain in Brain Immunity in the Oldest-Old Differentiates Cognitively Normal from Demented Individuals

doi: 10.1371/journal.pone.0007642

Figure Lengend Snippet: Significantly affected genes ( p <0.05) in the oldest-old (≥87 y.o.) cohort in comparison to cognitively intact youngest-old (≤86 y.o.) subjects.

Article Snippet: Blots were incubated with antibodies: rabbit anti-human CX3C chemokine fractalkine receptor 1, CX3CR1 (1∶500 v/v) from LifeSpan Biosciences Inc. (Seattle, WA); mouse anti-human HLA-DPA1 (1∶100 v/v) from Abnova (Walnut, CA); mouse mAb against human CD74 antigen protein (1∶1000 v/v), which recognizes cytoplasmic tail of CD74 (Cedarlane/StressMarq, Burlington, NC) and mouse anti-human β tubulin (TUBB; 1∶1000 v/v) – from Santa Cruz Biotech.

Techniques: Binding Assay

Journal: PLoS ONE

Article Title: Gain in Brain Immunity in the Oldest-Old Differentiates Cognitively Normal from Demented Individuals

doi: 10.1371/journal.pone.0007642

Figure Lengend Snippet: Expression analysis of the immune response genes in the inferior temporal cortex - BA20.

Article Snippet: Blots were incubated with antibodies: rabbit anti-human CX3C chemokine fractalkine receptor 1, CX3CR1 (1∶500 v/v) from LifeSpan Biosciences Inc. (Seattle, WA); mouse anti-human HLA-DPA1 (1∶100 v/v) from Abnova (Walnut, CA); mouse mAb against human CD74 antigen protein (1∶1000 v/v), which recognizes cytoplasmic tail of CD74 (Cedarlane/StressMarq, Burlington, NC) and mouse anti-human β tubulin (TUBB; 1∶1000 v/v) – from Santa Cruz Biotech.

Techniques: Expressing

Journal: PLoS ONE

Article Title: Gain in Brain Immunity in the Oldest-Old Differentiates Cognitively Normal from Demented Individuals

doi: 10.1371/journal.pone.0007642

Figure Lengend Snippet: Protein levels of CD74 were measured by Western Blot . Data expressed as means ± SEM of ODs normalized to the generic sample – “calibrator” and endogenous control - TUBB protein (N = 9–10/group, see ).

Article Snippet: Blots were incubated with antibodies: rabbit anti-human CX3C chemokine fractalkine receptor 1, CX3CR1 (1∶500 v/v) from LifeSpan Biosciences Inc. (Seattle, WA); mouse anti-human HLA-DPA1 (1∶100 v/v) from Abnova (Walnut, CA); mouse mAb against human CD74 antigen protein (1∶1000 v/v), which recognizes cytoplasmic tail of CD74 (Cedarlane/StressMarq, Burlington, NC) and mouse anti-human β tubulin (TUBB; 1∶1000 v/v) – from Santa Cruz Biotech.

Techniques: Western Blot

Journal: Vaccine

Article Title: Assessment of SARS-CoV-2 specific CD4(+) and CD8 (+) T cell responses using MHC class I and II tetramers

doi: 10.1016/j.vaccine.2021.03.008

Figure Lengend Snippet: SARS-CoV-2 peptide exchange with QuickSwitch HLA-A*02:01 Tetramer-PE molecules. 50 µg/mL Tetramerized and R-phycoerythrin coupled HLA-A*02:01 molecules were used for the peptide exchange experiment. All HLA-A*02:01 molecules were loaded with a exiting peptide and incubated with 20 µM of competing SARS-CoV-2 peptides for 4 h at room temperature (≈ 23 °C) in the presence of a kit-determined volume of Peptide Exchange Factor #1 (PEF#1). The amount of exiting peptide removed from the MHC molecule was then determined following a capture assay and plotted on the vertical axis for each tested peptide.

Article Snippet: 25 μL of a 100 μg/mL biotinylated MHC Class II QuickSwitch molecule was mixed with 3 μL of peptide stock diluted to 10 mM in 100% DMSO and 2 μL of Emulsifier #1 (MBLI: KXT-T07070 provided in the kit).

Techniques: Incubation

Journal: Vaccine

Article Title: Assessment of SARS-CoV-2 specific CD4(+) and CD8 (+) T cell responses using MHC class I and II tetramers

doi: 10.1016/j.vaccine.2021.03.008

Figure Lengend Snippet: SARS-CoV-2 peptide exchange with QuickSwitch HLA-DRB1*01:01, HLA-DRB1*04:01 and HLA-DRB1*15:01 molecules. 100 µg/mL recombinant HLA-DRB1*01:01 (Blue Bars), HLA-DRB1*04:01 (Orange Bars) and HLA-DRB1*15:01 (Gray Bars) molecules were used for the peptide exchange experiment. All MHC Class II molecules were loaded with a QuickSwitch exiting peptide and incubated with 1 mM of competing SARS-CoV-2 peptides overnight (greater than10 h) at 37 °C. The percentage of exiting peptide removed from the MHC molecule was then determined following a capture assay and plotted on the vertical axis for each tested peptide. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Article Snippet: 25 μL of a 100 μg/mL biotinylated MHC Class II QuickSwitch molecule was mixed with 3 μL of peptide stock diluted to 10 mM in 100% DMSO and 2 μL of Emulsifier #1 (MBLI: KXT-T07070 provided in the kit).

Techniques: Recombinant, Incubation

Journal: Vaccine

Article Title: Assessment of SARS-CoV-2 specific CD4(+) and CD8 (+) T cell responses using MHC class I and II tetramers

doi: 10.1016/j.vaccine.2021.03.008

Figure Lengend Snippet:

Article Snippet: 25 μL of a 100 μg/mL biotinylated MHC Class II QuickSwitch molecule was mixed with 3 μL of peptide stock diluted to 10 mM in 100% DMSO and 2 μL of Emulsifier #1 (MBLI: KXT-T07070 provided in the kit).

Techniques: